Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis

No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas

(2012) Rezvan Ahmadi et al.   JOURNAL OF NEURO-ONCOLOGY

Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors

(2012) Shingo Takano et al.   JOURNAL OF NEURO-ONCOLOGY

IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas

(2012) Tareq A. Juratli et al.   JOURNAL OF NEURO-ONCOLOGY

PROX1 is a predictor of survival for gliomas WHO grade II

(2011) T Elsir et al.   BRITISH JOURNAL OF CANCER

IDH1mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival

(2011) Niklas Thon et al.   CANCER

Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients

(2011) Akitake Mukasa et al.   CANCER SCIENCE

Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic?

(2011) C. Hartmann et al.   CLINICAL CANCER RESEARCH

IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas

(2011) Ichiyo Shibahara et al.   International Journal of Clinical Oncology

IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors

(2011) Marta Mellai et al.   JOURNAL OF NEURO-ONCOLOGY

Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05)

(2011) Oliver Grauer et al.   JOURNAL OF NEURO-ONCOLOGY

Value and Limitations of Immunohistochemistry and Gene Sequencing for Detection of theIDH1-R132HMutation in Diffuse Glioma Biopsy Specimens

(2011) Matthias Preusser et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China

(2011) S. Li et al.   NEURO-ONCOLOGY

The Global DNA Methylation Surrogate LINE-1 Methylation Is Correlated with MGMT Promoter Methylation and Is a Better Prognostic Factor for Glioma

(2011) Fumiharu Ohka et al.   PLoS One

Expression of pERK and pAKT in human astrocytomas: correlation with IDH1-R132H presence, vascular endothelial growth factor, microvascular characteristics and clinical outcome

(2011) Angelica A. Saetta et al.   VIRCHOWS ARCHIV

Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis

(2010) Philippe Metellus et al.   ACTA NEUROPATHOLOGICA

Molecular Classification of Low-Grade Diffuse Gliomas

(2010) Young-Ho Kim et al.   AMERICAN JOURNAL OF PATHOLOGY

IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

(2010) M. J. van den Bent et al.   CLINICAL CANCER RESEARCH

Segregation of non-p.R132H mutations inIDH1in distinct molecular subtypes of glioma

(2010) Lonneke A.M. Gravendeel et al.   HUMAN MUTATION

Molecular signatures classify astrocytic gliomas byIDH1mutation status

(2010) Grischa Toedt et al.   INTERNATIONAL JOURNAL OF CANCER

DNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in Glioma

(2010) Brock C. Christensen et al.   JNCI-Journal of the National Cancer Institute

First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response

(2010) W. Taal et al.   NEURO-ONCOLOGY

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas

(2010) C. Houillier et al.   NEUROLOGY

All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2

(2010) M. Labussiere et al.   NEUROLOGY

Monoclonal antibody specific for IDH1 R132H mutation

(2009) David Capper et al.   ACTA NEUROPATHOLOGICA

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

(2009) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Intrinsic Gene Expression Profiles of Gliomas Are a Better Predictor of Survival than Histology

(2009) L. A.M. Gravendeel et al.   CANCER RESEARCH

Analysis ofIDH1andIDH2mutations in Japanese glioma patients

(2009) Yukihiko Sonoda et al.   CANCER SCIENCE

IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas

(2009) S. Nobusawa et al.   CLINICAL CANCER RESEARCH

Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas

(2009) Marc Sanson et al.   JOURNAL OF CLINICAL ONCOLOGY

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

(2009) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide

(2009) H. J. Dubbink et al.   NEUROLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE